Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has ...

EPFL scientists have found that changing the "packaging" of DNA in neurons can turn memories on or off in mice.Our ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies ...

A researcher at the University of Houston finds management of diabetic ketoacidosis may center around reducing ketone levels in diabetic patients and ...

Robust efficacy data: ≥90% LDL-C reduction in non-human primates achieved within 48 hours of a single dose of EDIT-401; ≥90% LDL-C reduction in mice with high baseline LDL-C and reduced LDLR function ...

Colorectal cancer (CRC) remains one of the most prevalent cancers worldwide and a leading cause of cancer mortality. Despite ...

The Summer Research Showcase featured work that ranged from advancing cancer treatments to improving health care access. More ...

The global regenerative medicine market is poised for remarkable expansion, expected to record a compound annual growth rate (CAGR) of around 17% during the forecast period. This surge is primarily ...

Overview of Whole Genome Synthesis MarketThe global Whole Genome Synthesis Market is valued at USD 2.41 Billion in 2024 and is projected to reach a value of USD 12.21 Billion by 2035 at a CAGR ...

Q3 2025 Earnings Call October 28, 2025 8:30 AM EDTCompany ParticipantsJacob JohnsonOlivier Loeillot - President, ...

The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger ZURICH and NESS ZIONA, Israel, Oct. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasd ...